An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS.

Trial Profile

An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Panitumumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms PURO
  • Sponsors Wissenschaftlicher Service Pharma
  • Most Recent Events

    • 07 Mar 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 26 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 May 2012 Additional trial centre, investigator (Kurt Miller) identified, additional trial identifier (1032-01) identified and actual initiation date is 19 Apr 2011 as reported by German Clinical Trials Register record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top